Get the Stockscreener App
6.75
2.90%
0.19
After Hours:
6.75
Diamedica Therapeutics Inc stock is traded at $6.75, with a volume of 189.48K.
It is up +2.90% in the last 24 hours and up +3.21% over the past month.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
See More
Previous Close:
$6.56
Open:
$6.56
24h Volume:
189.48K
Relative Volume:
1.00
Market Cap:
$364.00M
Revenue:
-
Net Income/Loss:
$-35.10M
P/E Ratio:
-9.5731
EPS:
-0.7051
Net Cash Flow:
$-31.49M
1W Performance:
+5.63%
1M Performance:
+3.21%
6M Performance:
-13.13%
1Y Performance:
+25.70%
1-Day Range:
$6.49
$6.8873
1-Week Range:
$6.22
$6.9353
52-Week Range:
$5.245
$10.42
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Name
Diamedica Therapeutics Inc
Sector
Industry
Phone
(763) 496-5454
Address
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
6.75 | 351.60M | 0 | -35.10M | -31.49M | -0.7051 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-30-25 | Initiated | TD Cowen | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Jun-22-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-09-21 | Initiated | Oppenheimer | Outperform |
| Feb-17-21 | Initiated | ROTH Capital | Buy |
| Oct-30-20 | Initiated | Guggenheim | Buy |
| Jul-08-20 | Initiated | Maxim Group | Buy |
| Apr-30-19 | Initiated | Dougherty & Company | Buy |
| Mar-05-19 | Initiated | Lake Street | Buy |
View All
Diamedica Therapeutics Inc Stock (DMAC) Latest News
Price to earnings forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView
(DMAC) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
DiaMedica Therapeutics Inc. (DMAC) Key Financial Ratios – Valuation, Profitability & More - Value Research
DiaMedica Therapeutics Inc. (DMAC) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Four New York investor talks are planned for September by DiaMedica - Stock Titan
Understanding the Setup: (DMAC) and Scalable Risk - news.stocktradersdaily.com
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet - Yahoo Finance
DiaMedica Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
DiaMedica (DMAC) Results Versus Estimates: EPS Lands Above Forecast; Share Response: The Market Price Advances 1.82% in the Current UpdateManagement Tone Analysis - vinanet.vn
DiaMedica Therapeutics Inc (DMAC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
META_TITLE_QUOTE - Yahoo Finance
DiaMedica's DM199: Multiple Catalysts AheadWill It Deliver? - RTTNews
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript - AOL.com
DMAC Q2 2026 Earnings: Narrower-Than-Expected Loss Reflects Disciplined SpendingEBITDA Estimate Trend - Vinanet
DiaMedica Therapeutics (DMAC) Slips 1.04% as Shares Consolidate Between $6.35 Support and $7.01 ResistanceBPI Bear Correction - vinanet.vn
DiaMedica Therapeutics (DMAC) Edges Lower as Shares Consolidate Within Established RangeWatchlist Stock Ideas - vinanet.vn
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy - Yahoo Finance
What is HC Wainwright's Estimate for DMAC Q3 Earnings? - MarketBeat
DiaMedica Therapeutics Inc. (DMAC) stock price, news, quote and history - Yahoo Finance UK
DiaMedica Therapeutics (DMAC) CEO receives 60,200 RSU award vesting over four years - Stock Titan
DiaMedica Therapeutics CEO John Dietrich Pauls Awarded 60,200 Restricted Stock Units on August 10, 2026 - Kalkine Media
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ... - Yahoo Finance
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highli - GuruFocus
DiaMedica Expands Equity Incentive Pool With New S-8 Share Registration - TipRanks
DiaMedica Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
DiaMedica Therapeutics (DMAC) Advances Clinical Trials Amid High Price-to-Sales Valuation - GuruFocus
DiaMedica Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
DMAC Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
HC Wainwright Reaffirms Buy Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - MarketBeat
DiaMedica Therapeutics Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: DiaMedica Q2 2026 loss matches forecast as trials advance - Investing.com
DiaMedica Therapeutics Reports Q2 2026 Form 10-Q Highlighting Clinical Trial Enrollment Challenges - Kalkine Media
DiaMedica Advances Key Phase 2 Programs and Extends Cash Runway Through 2027 - TipRanks
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - BioSpace
DiaMedica Therapeutics (DMAC) Reports Positive Interim Data, Mar - GuruFocus
DiaMedica Q2 net loss widens to $10.1M as DM199 shows clinical promise - scanx.trade
DiaMedica Therapeutics (NASDAQ:DMAC) Issues Quarterly Earnings Results - MarketBeat
DiaMedica Therapeutics reports Q2 net loss $10.1M, cash $43.5M; advances DM199 clinical programs - TradingView
DiaMedica reports $10.1 million Q2 loss as DM199 trials advance - Quiver Quantitative
DiaMedica Therapeutics (NASDAQ: DMAC) increases R&D spend and loss in Q2 2026 - Stock Titan
DiaMedica Therapeutics (DMAC) Slips to $6.75 as Biotech Stock Consolidates Between Key Support and ResistanceSymmetrical Triangle - vinanet.vn
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
DiaMedica Therapeutics Inc (DMAC) Stock News Today - TradingKey
(DMAC) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Press Release: DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights - 富途牛牛
DiaMedica Therapeutics Inc (DMAC) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
DiaMedica Therapeutics (DMAC) Climbs 2.91% to $6.73: Key Levels and What to WatchSector Leader Stocks - vinanet.vn
Press Release: DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 - Moomoo
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 - Business Wire
DiaMedica Therapeutics (DMAC) Expected to Post Earnings on Tuesday - MarketBeat
1 Main Capital Highlights DiaMedica Therapeutics in Q2 2026 Letter - sekbernews.id
Diamedica Therapeutics Inc Stock (DMAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Diamedica Therapeutics Inc Stock (DMAC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STAHLBERG JAN | 10% Owner |
Nov 21 '25 |
Buy |
7.41 |
208,872 |
1,547,574 |
8,712,390 |
| STAHLBERG JAN | 10% Owner |
Nov 18 '25 |
Buy |
6.75 |
182,882 |
1,234,618 |
8,134,740 |
| STAHLBERG JAN | 10% Owner |
Nov 17 '25 |
Buy |
6.52 |
187,393 |
1,221,165 |
7,951,858 |
| STAHLBERG JAN | 10% Owner |
Nov 20 '25 |
Buy |
7.41 |
128,426 |
951,213 |
8,503,518 |
| STAHLBERG JAN | 10% Owner |
Nov 25 '25 |
Buy |
8.57 |
73,099 |
626,817 |
8,825,742 |
| STAHLBERG JAN | 10% Owner |
Nov 24 '25 |
Buy |
7.89 |
40,253 |
317,721 |
8,752,643 |
| Parsons James T. | Director |
Nov 21 '25 |
Option Exercise |
2.20 |
12,000 |
26,400 |
87,854 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):